Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Market Closed 06-12 16:00:00 EDT

1.22

+0.12

+10.91%

盘后1.26

+0.04+3.28%

19:59 EDT

High1.31	Low1.12	Vol38.10M
Open1.30	D1 Closing1.10	Amplitude17.27%
Mkt Cap195.20M	Tradable Cap175.68M	Total Shares160.00M
T/O47.07M	T/O Rate26.46%	Tradable Shares144.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":1.22,"timestamp":1781294400000,"preClose":1.1,"halted":0,"volume":38100685,"hourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.22,"latestTime":"19:59 EDT","volume":827874,"amount":1025325.7384,"timestamp":1781308781516,"change":0.04,"changeRate":0.032787,"amplitude":0.081967},"delay":0,"changeRate":0.10909090909090897,"floatShares":144000000,"shares":160000000,"eps":-1.083111,"marketStatus":"Market Closed","change":0.12,"latestTime":"06-12 16:00:00 EDT","open":1.3,"high":1.31,"low":1.12,"amount":47069571.008726,"amplitude":0.172727,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.083111,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.31,"preClose":1.1,"latestTime":"09:29 EDT","volume":4724904,"amount":6149540.516916,"timestamp":1781270999999,"change":0.21,"changeRate":0.190909,"amplitude":0.154545},"postHourTrading":{"tag":"盘后","latestPrice":1.26,"preClose":1.22,"latestTime":"19:59 EDT","volume":827874,"amount":1025325.7384,"timestamp":1781308781516,"change":0.04,"changeRate":0.032787,"amplitude":0.081967},"volumeRatio":1.9959754390836477,"impliedVol":1.9207,"impliedVolPercentile":0.5657},"requestUrl":"/m/hq/s/OTLK/tweets","defaultTab":"tweets","newsList":[{"id":"2640182080","title":"Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2640182080","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640182080?lang=en_us&edition=fundamental","pubTime":"2026-06-04 06:03","pubTimestamp":1780524228,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director Haddadin Yezan Munther bought 29,000 common shares in an open-market purchase.The shares were acquired at USD 0.83 each.Munther’s direct holding rose to 66,167 common shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL3VtC12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957679","title":"Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957679","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640957679?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:30","pubTimestamp":1780363847,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director and 10% owner Ghiath M. Sukhtian reported an indirect purchase of 8,539,709 common shares at USD 0.59.Indirect beneficial ownership rose to 22,092,068 common shares.Warrants held indirectly were reset to a USD 0.59 exercise price, covering 15,488,570 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLb19B5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640295284","title":"Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640295284","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640295284?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:16","pubTimestamp":1780319781,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  has resubmitted its biologics license application for ONS-5010, or Lytenava, for the treatment of neovascular age-related macular degeneration to the US Food and Drug Administration, the company said Monday.The resubmission comes after the company's successful appeal of the previously announced complete response letter for the drug, where the agency's Office of New Drugs concluded that substantial evidence of effectiveness had been established and no additional trials were required, according to a statement.The decision directed the Division of Ophthalmology and Office of Specialty Medicine to work with the company to reach an agreement on final product labeling, Outlook said.A Prescription Drug User Fee Act date and decision is expected within 60 days of the agency's receipt of the resubmission, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4588","BK4007","BK4585","BK4539","OTLK","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640095481","title":"Outlook Therapeutics resubmits FDA BLA for Lytneava in wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2640095481","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640095481?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:46","pubTimestamp":1780317982,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics resubmitted its BLA to the FDA for ONS-5010/LYTENAVA  to treat wet age-related macular degeneration.The FDA upheld the company’s appeal of a Complete Response Letter, concluding effectiveness evidence is sufficient, eliminating the need for additional trials.The resubmission was designated Class 1, setting an FDA decision deadline within 60 days of receipt.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL42C9fb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","OTLK","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","LU2095319765.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4585","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","BK4588","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954868","title":"Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for Ons-5010/Lytenava™ (Bevacizumab-Vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640954868?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:46","pubTimestamp":1780317960,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA5WXSPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640548149","title":"Outlook Therapeutics - FDA Says No Additional Trials Required for Lytenava in Namd","url":"https://stock-news.laohu8.com/highlight/detail?id=2640548149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640548149?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:46","pubTimestamp":1780317960,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA5WXSPG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639691611","title":"Outlook Therapeutics Prices Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2639691611","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639691611?lang=en_us&edition=fundamental","pubTime":"2026-05-29 05:25","pubTimestamp":1780003538,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  said late Thursday it priced a direct offering of over 8.5 million common shares at $0.5855 apiece for gross proceeds of $5 million.The offering is expected to be completed on May 29, subject to closing conditions, according to a statement.Net proceeds will be used for working capital and general corporate purposes, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","BK4139","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639616403","title":"Outlook to sell 8.54M shares at 58.55c in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2639616403","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639616403?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:08","pubTimestamp":1779998889,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8.54M ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-to-sell-8-54m-shares-at-58-55c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-to-sell-8-54m-shares-at-58-55c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639480615","title":"Outlook Therapeutics prices USD 5 million registered direct offering at USD 0.59 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2639480615","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639480615?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:00","pubTimestamp":1779998431,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics priced a registered direct offering of 8,539,709 common shares to GMS Ventures at USD 0.59 per share.Gross proceeds expected at USD 5 million; closing expected on or about May 29, 2026.Net proceeds earmarked for working capital, general corporate purposes.Agreed to reprice warrants for 15,488,570 shares held by GMS; weighted average exercise price cut to USD 0.59 from USD 1.78.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLxRZZz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0314104364.USD","LU1496350502.SGD","LU1778281490.HKD","LU1914381329.SGD","BK4550","IE00BWXC8680.SGD","LU2461242641.AUD","LU2095319765.USD","BK4534","LU1496350171.SGD","LU1162221912.USD","LU0943347566.SGD","LU1551013425.SGD","LU0820561909.HKD","LU1093756168.USD","LU0823434583.USD","LU1236620750.USD","IE00B1XK9C88.USD","IE00BKVL7J92.USD","LU0098860793.USD","BK4083","LU1989772840.SGD","IE00BKPKM429.USD","NDAQ","OTLK","LU0238689110.USD","LU1674673691.USD","LU2210150020.SGD","LU2756315318.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU0320765646.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4566","LU0689472784.USD","LU0823434740.USD","LU2210149790.SGD","BK4567","LU2361044865.SGD","LU1989772923.USD","BK4533","LU0820562030.AUD","HD","LU1035775433.USD","BK4588","LU0823411888.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639615195","title":"Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2639615195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639615195?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:00","pubTimestamp":1779998400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA39NBLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693633","title":"Outlook Therapeutics director Yezan Munther Haddadin acquires 34,000 common shares worth $14,960","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693633","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693633?lang=en_us&edition=fundamental","pubTime":"2026-05-28 03:25","pubTimestamp":1779909904,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director Haddadin Yezan Munther bought 34,000 common shares at USD 0.44 each, a Form 4 filing shows.Directly held stake rose to 37,167 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5Qt8FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638633368","title":"Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520","url":"https://stock-news.laohu8.com/highlight/detail?id=2638633368","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638633368?lang=en_us&edition=fundamental","pubTime":"2026-05-28 03:15","pubTimestamp":1779909346,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director Kurt J. Hilzinger bought 400,000 common shares in an open-market purchase.The shares were acquired at USD 0.44 each.Hilzinger’s direct holding rose to 423,655 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5TxN5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514725","title":"BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514725","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514725?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:27","pubTimestamp":1779798424,"startTime":"0","endTime":"0","summary":"BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment** Shares of drug developer Outlook Therapeutics OTLK.O rise 58% to 49 cents premarket** Co says it plans to resubmit a marketing application for its eye disease treatment in June after the U.S. FDA declined to approve it in December ** OTLK's treatment, Lytenava, targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina** In its formal response to an appeal from Outlook, the FDA concluded that substantial evidence of effectiveness for Lytenava has been established, OTLK says ** Lytenava is a specific, officially authorized formulation of FDA-approved drug bevacizumab** Up to last close, stock down 80% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4N4230S6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638511028","title":"Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava","url":"https://stock-news.laohu8.com/highlight/detail?id=2638511028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638511028?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:53","pubTimestamp":1779796426,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that the U.S. Food and Drug Administration, FDA, has granted the appeal following completion of the Formal Di...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-wins-appeal-following-fdr-process-for-ons-5010-lytenava-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-wins-appeal-following-fdr-process-for-ons-5010-lytenava-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4588","LENZ","OTLK","BK4539","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638516230","title":"Outlook Therapeutics Inc - to Resubmit Ons-5,010/Lytenava Bla in June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638516230","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638516230?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:05","pubTimestamp":1779793526,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230HZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638254516","title":"Outlook Therapeutics Inc - FDA Finds Substantial Evidence of Effectiveness for Lytenava in Namd","url":"https://stock-news.laohu8.com/highlight/detail?id=2638254516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638254516?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:05","pubTimestamp":1779793526,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638516485","title":"Outlook Therapeutics says FDA grants appeal on Lytenava effectiveness in nAMD review","url":"https://stock-news.laohu8.com/highlight/detail?id=2638516485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638516485?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:01","pubTimestamp":1779793304,"startTime":"0","endTime":"0","summary":"FDA granted Outlook Therapeutics’ appeal in a formal dispute resolution, finding substantial evidence of effectiveness for LYTENAVA in nAMD.The company expects to resubmit its LYTENAVA BLA in June 2026.The FDA indicated the filing should be a Class 1 resubmission, implying a decision within 60 days of receipt.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL7vgGMd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014021.USD","BK4585","BK4139","IE00BN0W2V16.EUR","NDAQ","SG9999014013.SGD","SG9999014039.USD","OTLK","LU2210150020.SGD","BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638427516","title":"Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638427516","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638427516?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:00","pubTimestamp":1779793200,"startTime":"0","endTime":"0","summary":"Company plans to resubmit BLA to the FDA in June 2026ISELIN, N.J., May  26, 2026  (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300933/0/en/Outlook-Therapeutics-Wins-Appeal-Following-Formal-Dispute-Resolution-Process-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022747","title":"Outlook Therapeutics Inc : Btig Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022747?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:45","pubTimestamp":1779101146,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635902058","title":"Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635902058","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635902058?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878851,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryOutlook Therapeutics Inc OTLK.OQ reported a quarterly adjusted loss of 16 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S25K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.5707},{"period":"1month","weight":4.3043},{"period":"3month","weight":2.0964},{"period":"6month","weight":-0.3838},{"period":"1year","weight":-0.337},{"period":"ytd","weight":-0.2278}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.330761},{"month":6,"riseRate":0.4,"avgChangeRate":0.024871},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}